D. Gary Gilliland has served as a director of the Company since April 1, 2014. Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center, a research organization, in Seattle, WA since January 31, 2020. From January 2, 2015 to January 30, 2020, Dr. Gilliland previously served as President and Director of the Fred Hutchinson Cancer Research Center. Prior to that, he was the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine from October 2013 to January 2015, where he was responsible for synthesizing research and clinical-care initiatives across all medical disciplines including cancer, heart and vascular medicine, neurosciences, genetics, and pathology, to create a national model for the delivery of precise, personalized medicine. From 2009 until he joined Penn Medicine in 2013, Dr. Gilliland was Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. At Merck, Dr. Gilliland oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials that included the development of pembrolizumab (anti-PD1) for treatment of cancer, and managed all preclinical and clinical oncology-licensing activities. Prior to joining Merck, Dr. Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute from 1996 to 2009, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center from 2002 to 2009, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute from 2004 to 2009. Dr. Gilliland has a Ph.D. in Microbiology from UCLA and an M.D. from UCSF. He is board-certified in Internal Medicine and had his Fellowship training in Hematology and Oncology, each at Harvard Medical School.
What is Dwight Gary Gilliland's net worth?
The estimated net worth of Dwight Gary Gilliland is at least $1.74 million as of July 30th, 2025. Gilliland owns 6,656 shares of Labcorp stock worth more than $1,740,012 as of December 4th. This net worth approximation does not reflect any other assets that Gilliland may own. Learn More about Dwight Gary Gilliland's net worth.
How do I contact Dwight Gary Gilliland?
Has Dwight Gary Gilliland been buying or selling shares of Labcorp?
Dwight Gary Gilliland has not been actively trading shares of Labcorp during the last ninety days. Most recently, Dwight Gary Gilliland sold 2,000 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $264.95, for a transaction totalling $529,900.00. Following the completion of the sale, the director now directly owns 6,656 shares of the company's stock, valued at $1,763,507.20. Learn More on Dwight Gary Gilliland's trading history.
Who are Labcorp's active insiders?
Labcorp's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Lance Berberian (EVP), Brian Caveney (EVP), Jonathan DiVincenzo (EVP and President, Central Laboratories and International), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Richelle Parham (Director), Adam Schechter (Chairman, President, and CEO), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Labcorp's active insiders.
Are insiders buying or selling shares of Labcorp?
During the last year, insiders at the medical research company sold shares 19 times. They sold a total of 54,892 shares worth more than $14,048,330.71. The most recent insider tranaction occured on November, 11th when CEO Adam H Schechter sold 5,745 shares worth more than $1,509,498.75. Insiders at Labcorp own 0.8% of the company.
Learn More about insider trades at Labcorp. Information on this page was last updated on 11/11/2025.
